Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...
Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to ...
PET-MPs may exacerbate IPF by inducing oxidative stress, mitochondrial damage, and inflammation in pulmonary cells, leading to chronic lung injury. The study identified AKT1, PIM1, and PIK3CD as core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results